Long-chain polyunsaturated fatty acids: Selected mechanisms of action on bone

Progress in Lipid Research

Volumn 49, Issue 4, 2010, Pages 438-449

  Kruger, M C ^a   Coetzee, M ^b   Haag, M ^b   Weiler, H ^c  

^a MASSEY UNIVERSITY   (New Zealand)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Bone; Long chain polyunsaturated fatty acids; LOX metabolites; Nitric oxide; Osteoblasts; Osteoclasts; PPAR ligands; Prostaglandins

Indexed keywords

ARACHIDONIC ACID; BONE MORPHOGENETIC PROTEIN; CD59 ANTIGEN; CYCLOOXYGENASE 2; CYTOKINE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; LINOLEIC ACID; LIPOXIN; LIPOXYGENASE; MESSENGER RNA; NITRIC OXIDE; OMEGA 3 FATTY ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN; PROSTAGLANDIN E2;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; CELL DIFFERENTIATION; CELL MATURATION; DIETARY INTAKE; FATTY ACID METABOLISM; HUMAN; MESENCHYMAL STEM CELL; MOLECULAR INTERACTION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; CELL DIFFERENTIATION; CYTOKINES; DIETARY FATS; FATTY ACIDS; FATTY ACIDS, UNSATURATED; HUMANS; MESENCHYMAL STEM CELLS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROSTAGLANDINS;

EID: 77956392414     PISSN: 01637827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plipres.2010.06.002     Document Type: Review

References (152)

1. NIH. Osteoporosis prevention D, and therapy. NIH Consensus Statement, vol. 17, March 27-29, 2000. p. 1-36.
2. B.A. Watkins, Y. Li, K.G.D. Allen, W.E. Hoffman, and M.F. Seifert Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats J Nutr 130 2000 2274 2284
3. D.B. Kettler Can manipulation of the ratios of essential fatty acids slow the rapid rate of postmenopausal bone loss? Altern Med Rev 6 2001 61 77
4. P. Albertazzi, and K. Coupland Polyunsaturated fatty acids. Is there a role in postmenopausal osteoporosis prevention Maturitas 42 2002 13 22
5. V.G. Borland, and C.M. Jackson Effects of a fat-free diet on the structure of the kidney in rats Arch Pathol 11 1931 687 708
6. G.J. Marum Roentgenograohic observations in age atrophy and osteoporosis of the spine Radiology 46 1946 220 226
7. R. Stepankova, D.P. Funda, and K. Smetana Essential fatty acid deficiency and bone fragility in rats Folia Biol 42 1996 257 259
8. M.C. Kruger, and D.F. Horrobin Calcium metabolism, osteoporosis and essential fatty acids: a review Prog Lipid Res 36 1997 131 151
9. P.P. Kokkinos, R. Shaye, B.S. Alam, and S.Q. Alam Dietary lipids, prostaglandin E2 levels, and tooth movement in alveolar bone of rats Calcif Tiss Int 53 1993 333 337
10. L.A. Weiss, E. Barrett-Connor, and D. von Mühlen Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo study Am J Clin Nutr 81 2005 934 938
11. P. Salari, A. Rezaie, B. Larijani, and M. Abdollahi A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis Med Sci Monit 14 2008 RA37 RA44
12. M.A. Moyad An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: Part I Urol Oncol 23 2005 28 35
13. T.G. Atkinson, H.J. Barker, and K.A. Meckling-Gill Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in post-weanling Fischer 344 rats Lipids 32 1997 293 302
14. A.P. Simopolous Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases Biomed Pharmacother 60 2006 502 507
15. P.C. Calder n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases Am J Clin Nutr 83 2006 1505S 1519S
16. G.C. Burdge, and P.C. Calder Dietary α-linolenic acid and health-related outcomes: a metabolic perspective Nutr Res Rev 19 2006 26 52
17. G.C. Burdge Metabolism of α-linolenic acid in humans Prostaglandin Leukot Essent Fatty Acid 75 2006 161 168
18. C.N. Serhan Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes and neuroprotectins Curr Opin Clin Nutr Metab Care 8 2005 115 121
19. C.N. Serhan, S. Hong, K. Gronert, S.P. Colgan, P.R. Devchand, and G. Mirick Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammatory signals J Exp Med 196 2002 1025 1037
20. H. Kuhn, and V.B. O'Donnell Inflammation and immune regulation by 12/15-lipoxygenases Prog Lipid Res 45 2006 334 356
21. R.F. Shen, and H.H. Tai Thromboxanes: synthase and receptors J Biomed Sci 5 1998 153 172
22. N.M. Davies, R.L. Good, K.A. Roupe, and J.A. Yanez Cyclo-oxugenase-3: axiom, dogma, anomaly, enigma or splice error? Not as easy as 1, 2, 3 J Pharm Sci 7 2004 217 226
23. B. Watkins, H. Lippman, L. Le Boutellier, Y. Li, and M. Seifert Bioactive fatty acids: role in bone biology and bone cell function Prog Lipid Res 40 2001 125 148
24. D. Sun, A. Krishnan, K. Zaman, R. Lawrence, A. Bhattacharya, and G. Fernandes Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice J Bone Miner Res 18 2003 1206 1216
25. R.C. Poulsen, K. Gotlinger, C.N. Serhan, and M.C. Kruger Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega 3 intake Am J Hematol 83 2008 437 445
26. M. Coetzee, M. Haag, A.M. Joubert, and M.C. Kruger Effects of arachidonic acid, docosahexaenoic acid and prostaglandin E2 on cell proliferation and morphology of MG-63 and MC3T3-E1 osteoblast-like cells Prostaglandin Leukot Essent Fatty Acid 76 2007 35 45
27. M.C. Kruger, and L.M. Schollum Is docosahexaenoic acid more effective than eicosapentaenoic acid for increasing calcium bioavailability Prostaglandin Leukot Essent Fatty Acid 73 2005 327 334
28. B.A. Watkins, Y. Li, H.E. Lippman, and M.F. Seifert Omega-3 polyunsaturated fatty acids and skeletal health Exp Biol Med 226 2001 485 497
29. Y. Li, M.F. Seifert, D.M. Ney, M. Grahn, A.L. Grant, and K.G.D. Allen Dietary conjugated linoleic acids alter serum IGF-I and IGF binding protein concentrations and reduce bone formation in rats fed (n-6) or (n-3) fatty acids J Bone Miner Res 14 1999 1153 1162
30. B.Y.Y. Lau, W.E. Ward, J.X. Kang, and D.W.L. Ma Femur EPA and DHA are correlated with femur biomechanical strength in young fat-1 mice J Nutr Biochem 20 2009 453 461
31. H.T. Baird, D.L. Eggett, and S. Fullmer Varying ratios of omega 6:omega 3 fatty acids on the pre- and postmortem mineral density, bone ash and bone breaking strength of laying chickens Poult Sci 87 2008 323 328
32. B.A. Watkins, Y. Li, H.E. Lipman, and S. Feng Modulatory effect of omega 3 polyunsaturated fatty acids on osteoblast function and bone metabolism Prostaglandin Leukot Essent Fatty Acid 68 2003 387 398
33. G. Fernandes, A. Bhattacharaya, M. Rahman, K. Zaman, and J. Banu Effects of n-3 fatty acids on autoimmunity and osteoporosis Front Biosci 13 2008 4015 4020
34. R.P. Heaney, R. Carey, and L. Harkness Roles of vitamin D, n-3 polyunsaturated fatty acid, and soy isoflavones in bone health J Am Diet Assoc 2005 1700 1702
35. U.N. Das Essential fatty acids and osteoporosis Nutrition 16 2000 386 390
36. C. Shen, J.K. Yeh, J. Rasty, Y. Li, and B.A. Watkins Protective effect of dietary long-chain n-3 polyunsaturated fatty acids on bone loss in gonad-intact middle-aged male rats Br J Nutr 95 2006 462 468
37. 2 study Am J Clin Nutr 85 2007 803 807
38. M.C. Kruger, H. Coetzer, R. de Winter, G. Gericke, and D.H. van Papendorp Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis Aging Clin Exp Res 10 1998 385 394
39. E.J. Bassey, J.E. Lettlewood, M.C. Rothwell, and D.W. Pye Lack of effects of supplementation with essential fatty acids one bone mineral density in health pre- and postmenopausal women: two randomised controlled trials of Efacal versus calcium alone Br J Nutr 83 2000 629 635
40. A.E. Griel, P.M. Kris-Etherton, K.F. Hilpert, G.Z. Zhao, S.G. West, and R.L. Corwin An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans Nutr J 6 2007 1 8
41. A. Trichopoulos, E. Georgio, Y. Bassiakos, L. Lipworth, P. Lagiou, and C. Proukakis Energy intake and monounsaturated fat in relation to bone mineral density among women and men in Greece Prev Med 26 1997 395 400
42. H.M. MacDonald, S.A. New, M.H. Golden, M.K. Campbell, and D.M. Reid Nutritional associations with bone loss during the menopausal transition: evidence of a beneficial effect of calcium, alcohol and fruit and vegetable nutrients and of a detrimental effect of fatty acids Am J Clin Nutr 79 2004 155 165
43. M.J. Martinez-Ramirez, S. Palma, M.A. Martinez-Gonzalez, A.D. Delgado-Martinez, C. De la Fuente, and M. Delgado-Rodriques Dietary fat intake and the risk of osteoporotic fractures in the elderly Eur J Clin Nutr 61 2007 1114 1120
44. R.L. Corwin, T.J. Hartman, S.A. Macsuga, and B.I. Graubard Dietary saturated fat intake is inversely associated with bone density in humans: analysis of NHANES III J Nutr 136 2006 159 165
45. D.A. Collins, and T.J. Chambers Effect of prostaglandins E1, E2, and F2a on osteoclast formation in mouse bone marrow cultures J Bone Miner Res 6 1991 157 164
46. W.S.S. Jee, and Y.F. Ma The in vivo anabolic actions of prostaglandins in bone Bone 21 1997 297 304
47. T.L. McCarthy, M. Centrella, L.G. Raisz, and E. Canalis Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone Endocrinology 128 1991 2895 2900
48. R.L. Corwin Effects of dietary fats on bone health in advanced age Prostaglandin Leukot Essent Fatty Acid 68 2003 379 386
49. H.A. Weiler, and S.C. Fitzpatrick-Wong Dietary long-chain polyunsaturated fatty acids minimize dexamethasone-induced reductions in arachidonic acid status but not bone mineral content in piglets Pediatr Res 51 2002 282 289
50. L.G. Raisz, C.B. Alander, and H.A. Simmons Effects of prostaglandin E3 and eicosapentaenoic acid on rat bone in organ culture Prostaglandins 37 1989 615 625
51. O. Laneuville, D.K. Breuer, N. Xu, Z.H. Huang, D.A. Gage, and J.T. Watson Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2 J Biol Chem 270 1995 19330 19336
52. S.C. Cunnane, and B.A. Griffin Nutrition and metabolism of lipids M.J. Gibney, H.H. Vorster, F.J. Kok, Introduction to human nutrition 1st ed. 2002 Blackwell Science Oxford 81 115
53. J.B. Barham, M.B. Edens, A.N. Fonteh, M.M. Johnson, L. Easter, and F.H. Chilton Addition of eicosapentaenoic acid to γ-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans J Nutr 130 2000 1925 1931
54. V.D. Lucia, S.C. Fitzpatrick-Wong, and H.A. Weiler Dietary arachidonic acid suppresses bone turnover in contrast to low dosage exogenous prostaglandin E2 that elevates bone formation in the piglet Prostaglandin Leukot Essent Fatty Acid 68 2003 407 413
55. H.A. Weiler Dietary supplementation of arachidonic acid is associated with higher whole body weight and bone mineral density in growing pigs Pediatr Res 47 2000 692 697
56. A. Burke, and H. Weiler The effect of prostaglandin E2 (PGE2) and long-chain polyunsaturated fatty acids (LC PUFA) on bone formation in piglets: a model for bone growth in nutritional investigation Prostaglandin Leukot Essent Fatty Acid 67 2002 229 235
57. H.A. Weiler, and S.C. Fitzpatrick-Wong Modulation of essential (n-6):(n-3) fatty acids ratio alters fatty acid status but not bone mass in piglets J Nutr 132 2002 2667 2672
58. B.A. Watkins, C.L. Shen, K.G.D. Allen, and M.F. Seifert Dietary (n-3) and (n-6) polyunsaturates and acetylsalicylic acid alter ex vivo PGE2 biosynthesis, tissue IGF-I levels, and bone morphometry in chicks J Bone Miner Res 11 1996 1321 1332
59. X.Y. Tian, Q. Zhang, R.B. Setterberg, Q.Q. Zeng, S.J. Iturria, and Y.F. Ma Continuous PGE2 leads to net bone loss while intermittent PGE2 leads to net bone gain in lumbar vertebral bodies of adult female rats Bone 42 2008 914 920
60. Q. Gao, M. Xu, C.B. Alander, S. Choudhary, C.C. Pilbeam, and L.G. Raisz Effects of prostaglandin E2 on bone in mice in vivo Prostaglandin Other Lipid Mediat 89 2009 20 25
61. T. Tsujisawa, H. Inoue, and T. Nishihara SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL J Bone Miner Res 20 2005 15 22
62. X. Li, Y. Okada, C.C. Pilbeam, J.A. Lorenzo, C.R.J. Kennedy, and R.M. Breyer Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro Endocrinology 141 2000 2054 2061
63. K. Ono, H. Kaneko, S. Choudhary, C.C. Pilbeam, J.A. Lorenzo, and T. Akatsu Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor J Bone Miner Res 20 2005 23 29
64. R. Tsutsumi, C. Xie, X. Wei, M. Zhang, X. Zhang, and L.M. Flick PGE2 signaling through the EP4 receptor on fibroblasts upregulates RANKL and stimulates osteolysis J Bone Miner Res 24 2009 1753 1762
65. X.H. Liu, A. Kirschenbaum, S. Yao, and A.C. Levine Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system Ann NY Acad Sci 1068 2006 225 233
66. H. Kaneko, M. Mehrotra, C. Alander, U. Lerner, C. Pilbeam, and L. Raisz Effects of prostaglandin E2 and lipopolysaccharide on osteoclastogenesis in RAW 264.7 cells Prostaglandin Leukot Essent Fatty Acid 77 2007 181 186
67. I. Take, Y. Kobayashi, Y. Yamamoto, H. Tsuboi, T. Ochi, and S. Uematsu Prostaglandin E2 strongly inhibits human osteoclast formation Endocrinology 146 2005 5204 5214
68. T. Minamizaki, Y. Yoshiko, K. Kozai, J.E. Aubin, and N. Maeda EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures Bone 44 2009 1177 1185
69. M. Weinreb, D. Shamir, M. Machwate, G.A. Rodan, S. Harada, and S. Keila Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity Prostaglandin Leukot Essent Fatty Acid 75 2006 81 90
70. K. Suda, N. Udagawa, N. Sato, M. Takami, K. Itoh, and J.-T. Woo Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lypopolysaccharide induced osteoclast formation J Immunol 172 2004 2504 2510
71. G.O. Ramirez-Yanez, S. Hamlet, A. Jonarta, G.J. Seymour, and A.L. Symons Prostaglandin E2 enhances transforming growth factor-beta 1 and TGF-beta receptor synthesis: an in vivo and in vitro study Prostaglandin Leukot Essent Fatty Acid 74 3 2006 183 192
72. Y. Tang, X. Wu, W. Lei, L. Pang, C. Wan, and Z. Shi TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation Nat Med 15 2009 757 765
73. S. Sankar, N. Mahooti-Brooks, M. Sentrella, T.L. McCarthy, and J.A. Madri Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2 J Biol Chem 270 1995 13567 13572
74. T.L. McCarthy, T.H. Pham, B.I. Knoll, and M. Centrella Prostaglandin E2 increases transforming growth factor-β type ii receptor expression through CCAAT enhancer-binding protein δ in osteoblasts Mol Endocrinol 21 2007 2713 2724
75. B.A. Watkins, and M.F. Seifert Conjugated linoleic acid and bone biology J Am Coll Nutr 19 2000 478S 486S
76. C. Schmid, I. Schläpfer, M. Waldvogel, J. Zapf, and E.R. Froesch Prostaglandin E2 stimulates synthesis of insulin-like growth factor binding protein-3 in rat bone cells in vitro J Bone Miner Res 7 1992 1157 1163
77. A.M. Delany, J.M. Pash, and E. Canalis Cellular and clinical perspectives on skeletal insulin-like growth factor I J Cell Biochem 55 1994 328 333
78. J.R. Lieberman, A. Daluiski, and T.A. Einhorn The role of growth factors in the repair of bone. Biology and clinical applications J Bone Joint Surg 84A 2002 1032 1044
79. T.L. McCarthy, S. Casinghino, M. Centrella, and E. Canalis Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: regulation by prostaglandin E2, growth hormone, and the insulin-like growth factors J Cell Physiol 160 1994 163 175
80. Y. Wang, S. Nishida, H.Z. Elalieh, R.K. Long, B.P. Halloran, and D.D. Bikle Role of IGF-1 signalling in regulating osteoclastogenesis J Bone Miner Res 21 2006 1350 1358
81. J.A. DiBattista, S. Dore, N. Morin, and T. Abribat Prostaglandin E2 up-regulates insulin-like growth factor binding protein-3 expression and synthesis in human articular chondrocytes by a c-AMP-independent pathway: role of calcium and protein kinase A and C J Cell Biochem 63 1996 320 333
82. L.G. Raisz Bone cell biology: new approaches and unanswered questions Bone Miner Res 8 1993 S457 S465
83. Y. Hakeda, H. Kawaguchi, A. Hand, C. Pilbeam, M. Hurley, and C. Abreu J Bone Miner Res 8 1993 S237
84. E.J. Kim, W.Y. Kim, Y.H. Kang, Y.L. Ha, L.A. Back, and J.H.Y. Park Inhibition of Caco-2 cell proliferation by n-3 fatty acids: possible mediation by increased secretion of insulin-like growth factor binding protein-6 Nutr Res 20 2000 1409 1421
85. P. Bianco, M. Riminucci, S. Gronthos, and P.G. Robey Bone marrow stromal stem cells: nature, biology, and potential applications Stem Cell 19 2001 180 192
86. S. Maeda, T. Nobukuni, K. Simo-Onoda, K. Hayashi, K. Yone, and S. Komiya Sortilin is upregulated during osteoblastic differentiation of mesenchymal stem cells and promotes extracellular matrix mineralization J Cell Physiol 193 2002 73 79
87. P. Ducy, R. Zhang, V. Geoffroy, A.L. Ridall, and G. Karsenty Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation Cell 89 1997 747 754
88. G. Karsenty Minireview: transcriptional control of osteoblast differentiation Endocrinology 142 2001 2731 2733
89. I. Takada, and S. Kato Molecular mechanism of switching adipocyte/osteoblast differentiation through regulation of PPAR-gamma function Clin Calcium 18 2008 656 661
90. C.J. LeBlanc, D.W. Horohov, J.E. Bauer, G. Hosgood, and G.E. Mauldin Effect of dietary supplementation with fish oil on in vivo production of inflammatory mediators in clinically normal dogs Am J Vet Res 69 2008 486 493
91. X. Zhang, E.M. Schwartz, D.A. Young, J.E. Puzas, R.N. Rosier, and R.J. O'Keefe Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair J Clin Invest 109 2002 1405 1415
92. T. Arikawa, K. Omura, and I. Morita Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells J Cell Physiol 200 2004 400 406
93. J. Skillington, L. Choy, and R. Derynck Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes J Cell Biol 159 2002 135 146
94. C. Liu, E. Chang, J. Yu, C.S. Carlson, L. Prazak, and X.P. Yu The interferon-inducible p204 protein acts as a transcriptional coactivator of Cbfa1 and enhances osteoblast differentiation J Biol Chem 280 2005 2788 2796
95. C. Giaginis, A. Tsantili-Kakoulidou, and S. Theocharis Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism Fundam Clin Pharmacol 21 2007 231 244
96. S.L. Holmen, C.R. Zylstra, A. Mukherjee, R.E. Sigler, and M.-C. Faugere Essential role of beta-catenin in postnatal bone acquisition J Biol Chem 280 2005 21162 21168
97. F. Boyce, and L. Xing Functions of RANKL/RANK/OPG in bone modeling and remodeling Arch Biochem Biophys 473 2008 139 146
98. R.C. Poulsen, F. Wolber, P.J. Moughan, and M.C. Kruger Long chain polyunsaturated fatty acids alter membrane bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells Prostaglandin Lipid Mediat 85 2008 42048
99. M. Coetzee, M. Haag, and M.C. Kruger Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E2 (PGE2) and parathyroid hormone on osteoprotegerin (OPG) and RANKL secretion by MC3T3-E1 osteoblast-like cells J Nutr Biochem 18 2007 54 63
100. A. Bhattacharya, M. Rahman, J. Banu, R.A. Lawrence, H.S. McGuff, and I.R. Garrett Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Faslpr mice by n-3 fatty acids J Am Coll Nutr 24 2005 200 209
101. M.D. Rahman, A. Bhattacharya, and G. Fernandes Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells that eicosapentaenoic acid J Cell Physiol 214 2008 201 209
102. H. Hasturk, A. Kantarci, T. Ohira, M. Arita, N. Ebrahimi, and N. Chiang RvE1 protects from local inflammation and osteoclst-mediated bone destruction in perionditis FASEB 20 2006 401 403
103. J. Cornish, A. Macgibbon, J. Lin, K.E. Callon, P.C. Tong, and J.E. Dunford Modulation of osteoclastogenesis by fatty acids Endocrinology 149 2008 5688 5695
104. M.C. Horowitz Cytokines and estrogen in bone: anti-osteoporotic effects Science 260 1993 626 627
105. G.E. Caughey, E. Mantizioris, R.A. Gibson, L.G. Cleland, and M.J. Jameset The effect on human TNF alpha and IL-1 Beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil Am J Clin Nutr 63 1996 116 122
106. N. Claassen, H.C. Potgieter, M. Seppa, W.J.H. Vermaak, H. Coetzer, and D.H. van Papendorp Supplemented gamma-linolenic acid and eicosapentaenoic acid influence bone status in young male rats: effects on free urinary collagen crosslinks, total urinary hydroxyproline, and bone calcium content Bone 16 1995 385S 392S
107. B.J. Votta, and D.R. Bertolis Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro Bone 15 1994 533 538
108. G. Priante, L. Bordin, E. Musacchio, G. Clari, and B. Baggio Fatty acids and cytokine mRNA expression in human osteoblastic cells: a specific effect of arachidonic acid Clin Sci 102 2002 403 409
109. L. Bordin, G. Priante, E. Musacchio, S. Giunco, E. Tibaldi, and G. Clari Arachidonic acid-induced IL-6 expression is mediated by PKC alpha activation in osteoblastic cells Biochemistry 42 2003 4485 4491
110. I.H. Skuladottir, D.H. Petursdottir, and I. Hardardottir The effects of omega 3 polyunsaturated fatty acids on TNF-alpha and IL-10 secretion by murine peritoneal cells in vitro Lipids 42 2007 699 706
111. A. Bhattacharya, M. Rahman, D. Sun, and G. Fernandes Effect of fish oil on bone density in ageing C57BL/6 female mice J Nutr Biochem 18 2007 372 379
112. S.L. Cohen, A.M. Moore, and W.E. Ward Flaxseed oil and inflammation-associated bone abnormalities in interleukin-10 knockout mice J Nutr Biochem 16 2005 368 374
113. L. Zeitlin, E. Segev, A. Fried, and S. Wientroub Effects of long-term administration of n-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice J Cell Biochem 90 2003 347 360
114. G.A. Miggiano, and L. Gagliardi Diet, nutrition and bone health Clin Ther 156 2005 47 56
115. X. Liu, A. Kirschenbaum, S. Yao, and A.C. Levine Cross-talk between interleukin-6 and prostaglandin E2 signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-κB (RANK) ligand/RANK system Endocrinology 146 2005 1991 1998
116. D. Bragga, L. Wang, R. Farias-Eisner, J.A. Glaspy, and S.T. Reddy Differential effects of prostaglandin derived ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion PNAS 100 2003 1751 1756
117. G. Bannenberg, N. Chiang, A. Ariel, M. Arita, E. Tjonahen, and K.H. Gotlinger Molecular circuits of resolution: formation and actions of resolvins and protectins J Immunol 174 2005 4345 4355
118. G. Bannenberg, R.L. Moussignac, K. Gronert, P.R. Devchand, B.A. Schmidt, and W.J. Guilford Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration Br J Pharmacol 143 2004 43 52
119. B.S. Herrera, L. Gao, K. Omori, R. Yang, M. Zhu, and M.N. Muscara An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption Br J Pharmacol 155 2008 43 52
120. C.L. Shen, J. Peterson, O.L. Tatum, and D.M. Dunn Effect of long chain n-3 polyunsaturated fatty acids on inflammation mediators during osteoblastogenesis J Med Food 11 2008 105 110
121. G. Priante, E. Musacchio, E. Pagnin, L.A. Calo, and B. Baggio Specific effect of arachidonic acid on inducible nitric oxide synthase (iNOS) mRNA expression in human osteoblastic cells Clin Sci 109 2005 177 182
122. X. Fan, E. Roy, L. Zhu, T.C. Murphy, C. Ackert-Bicknell, and C.M. Hart Nitric oxide regulates receptor activator of nuclear factor-kB ligand and osteoprotegerin expression in bone marrow stromal cells Endocrinology 145 2004 751 759
123. U.N. Das Nitric oxide as the mediator of the antiosteoporotic actions of estrogen, statins, and essential fatty acids Exp Biol Med 227 2002 88 93
124. S.D. Clarke The multidimensional regulation of gene expression by fatty acids: polyunsaturated fatty acids as nutrient sensors Curr Opin Lipidol 15 2004 13 18
125. H. Sampath, and J.M. Ntambi Polyunsaturated fatty acid regulation of gene expression Nutr Rev 62 2004 333 339
126. I. Issemann, and S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
127. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev 20 1999 649 688
128. C. Juge-Aubry, A. Pernin, T. Favez, A.G. Burger, W. Wahli, and C.A. Meier DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements: importance of the 5′-flanking region J Biol Chem 272 1997 25252 25259
129. P.W. Jurutka, I. Bartik, G.K. Whitfield, D.R. Mathern, T.K. Barthel, and M. Gurevich Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands J Bone Miner Res 22 2007 V2 V10
130. Y. Wan, L.W. Chong, and R.M. Evans PPAR-γ regulates osteoclastogenesis in mice Nat Med 13 2007 1496 1503
131. C.L. Ackert-Bicknell, S. Demissie, C.M. Evsikova, Y.-H. Hsu, V.E. deMambro, D. Karasik, and C.J. Rosen PPARG by dietary fat interaction influences bone mass in mice and humans J Bone Miner Res 23 2008 1398 1408
132. B. Lecka-Czernik, C.L. Ackert-Bicknell, M.L. Adamo, V. Marmolejos, G.A. Churchill, and K. Shockley Activation of peroxisome proliferator-activated receptor-γ (PPARγ) by rosiglitazone suppresses components of the IGF regulatory system in vitro and in vivo Endocrinology 148 2007 903 911
133. D.D. Diascro, R.L. Vogel, T.E. Johnson, K.M. Witherup, S.M. Pitzenberger, and S.J. Rutledge High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells J Bone Miner Res 13 1998 96 106
134. M.E. Nuttal, A.J. Patton, D.L. Olivera, D.P. Nadeau, and M. Gowen Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders J Bone Miner Res 13 1998 381
135. B. Lecka-Czernik, I. Gubrij, E.J. Moerman, O. Kajkenova, D.A. Lipschitz, and S.C. Manolagas Inhibition of Osf/Cbfa 1 expression and terminal osteoblast differentiation bt PPARγ2 J Cell Biochem 74 1999 357 371
136. T.H. Lin, R.S. Yang, C.H. Tang, C.P. Lin, and W.M. Fu PPARγ inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats Bone 41 2007 562 574
137. S.M. Jackson, and L.L. Demer Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts FEBS Lett 471 2000 119 124
138. T. Hasegawa, K. Oizumi, Y. Yoshiko, K. Tanne, N. Maeda, and J.E. Aubin The PPARgamma-elective ligand BRL-49653 differentially regylates the fate choices of rat calvaria versus rat bone marrow stromal cell populations BMC Dev Biol 8 2008 71
139. I. Takada, and S. Kato A new PPAR-γ function in bone IBMS BoneKEy 5 2008 258 261
140. B. Lecka-Czernik, E.J. Moerman, D.F. Grant, J.M. Lehmann, S.C. Manolagas, and R.L. Jilka Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation Endocrinology 143 2002 2376 2384
141. S.A. Kliewer, S.S. Sundseth, S.A. Jones, P.J. Brown, G.B. Wisely, and C.S. Koble Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proc Natl Acad Sci USA 94 1997 4318 4323
142. R. Berger, and D. Moller The mechanisms of action of PPARγ Annu Rev Med 53 2002 409 435
143. K. Still, P. Grabowski, I. Mackie, M. Perry, and N. Bishop The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo Calcif Tiss Int 83 2008 285 292
144. S. Kersten, B. Desvergne, and W. Wahli Role of PPARs in health and disease Nature 405 2000 421 424
145. E.D. Rosen, and B.M. Spiegelman PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth J Biol Chem 276 2001 37731 37734
146. A.C. Maurin, P.M. Chavassieux, and P.J. Meunier Expression of PPARγ and β/δ in human primary osteoblastic cells: influence of polyunsaturated fatty acids Calcif Tiss Int 76 2005 385 392
147. M. Abedin, J. Lim, T.B. Tang, D. Park, L.L. Demer, and Y. Tintut n-3 Fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-γ pathways Circ Res 98 2006 727 729
148. S.A. Fyffe, M.S. Alphey, L. Buetow, T.K. Smith, M.A.J. Ferguson, and M.D. Sørensen Recombinant human PPAR-β/δ ligand binding domain is locked in an activated conformation by endogenous fatty acids J Mol Biol 356 2006 1005 1013
149. M. Mehrabian, H. Allayee, J. Stockton, P. Lum, T. Drake, and L. Castellani Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits Nat Genet 37 2005 1224 1233
150. U. Syversen, A.K. Stunes, B.I. Gustafsson, K.J. Obrant, L. Nordsletten, and R. Berge Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone BMC Endocr Disord 9 2009 10
151. T. Shibata, S. Takeuchi, S. Yokota, K. Kakimoto, F. Yonemori, and K. Wakitani Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats Br J Pharmacol 130 2000 495 504
152. R.C. Poulsen, P.J. Moughan, and M.C. Kruger Long chain fatty acids and the regulation of bone metabolism Exp Biol Med 232 2007 1275 1288